Michael J. Cork
A5026963044- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Neonatal skin health care
- Psoriasis: Treatment and Pathogenesis
- Advancements in Transdermal Drug Delivery
- Adrenal Hormones and Disorders
- Autoimmune Bullous Skin Diseases
- IL-33, ST2, and ILC Pathways
- Transgenic Plants and Applications
- Pharmaceutical studies and practices
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Pediatric health and respiratory diseases
- Nail Diseases and Treatments
- Cytokine Signaling Pathways and Interactions
- Complementary and Alternative Medicine Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cutaneous lymphoproliferative disorders research
- Hematopoietic Stem Cell Transplantation
- melanin and skin pigmentation
- Pressure Ulcer Prevention and Management
University of Sheffield
2016-2025
Sheffield Children's Hospital
2013-2025
Sheffield Children's NHS Foundation Trust
2011-2025
Royal Hallamshire Hospital
2008-2024
Sheffield Teaching Hospitals NHS Foundation Trust
2013-2024
Hospital Infantil Universitario Niño Jesús
2022-2023
Fundación Instituto Valenciano de Oncología
2022-2023
Helsinki University Hospital
2022-2023
Aristotle University of Thessaloniki
2022-2023
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2022-2023
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of and interleukin-13, type 2 cytokines that may be important drivers atopic or allergic diseases such as dermatitis.
BackgroundAtopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and increasing prevalence. Because of the significant socioeconomic effect atopic its on quality life families, there have been decades research focused prevention, with limited success. Recent advances cutaneous biology suggest barrier defects might be key initiators possibly allergic sensitization.ObjectiveOur objective was to test whether...
Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) widely used, potent immunosuppressant but it not effective in all patients with atopic dermatitis, and side‐effects limit its use. Dupilumab, fully human anti‐interleukin 4 receptor‐alpha monoclonal antibody, inhibits signaling of IL‐4 IL‐13, key drivers Type 2/Th2‐mediated inflammation, approved the U.S.A. European Union for treatment inadequately‐controlled moderate‐to‐severe...
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements AD signs symptoms. Objectives To evaluate the efficacy safety of monotherapy adults moderate-to-severe who had an inadequate response to treatments. Methods two 52-week, randomized, double-blind,...
Abstract Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis made using evaluated clinical criteria. Disease activity and burden are best measured with composite score, assessing both objective subjective symptoms, such as SCORing Dermatitis (SCORAD). AD management must take into account pathogenic variabilities, the patient’s age also target flare prevention. Basic therapy includes hydrating barrier‐stabilizing topical treatment universally applied,...
Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in U.S.A. patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use medicines, Japan whose AD existing therapies, Europe are candidates systemic therapy maintenance treatment of asthma their current medicines. trials have reported increased incidence conjunctivitis dupilumab vs. placebo. To characterize further...
Children with severe atopic dermatitis (AD) have limited treatment options.We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years AD inadequately controlled therapies.In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300 mg every 4 weeks (300 q4w), a weight-based regimen 2 (100 q2w, baseline weight <30 kg; 200 ≥30 kg), or placebo; concomitant medium-potency TCS.Both q4w q2w TCS regimens...
Abstract Linked Comment: Akel and Fuller. Br J Dermatol 2018; 178:823–824. Plain language summary available online
BackgroundSkin barrier dysfunction precedes eczema development. We tested whether daily use of emollient in the first year could prevent high-risk children.MethodsWe did a multicentre, pragmatic, parallel-group, randomised controlled trial 12 hospitals and four primary care sites across UK. Families were approached via antenatal or postnatal services for recruitment term infants (at least 37 weeks' gestation) at high risk developing (ie, one first-degree relative with parent-reported eczema,...
Plain language summary available online
Plain language summary available online
For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe atopic dermatitis (AD), 16 weeks of treatment dupilumab resulted in substantial clinical benefit compared placebo, an acceptable safety profile. However, long-term data on the approved dose regimens adolescents AD are lacking. This open-label extension study (LIBERTY PED-OLE, NCT02612454) reports safety, efficacy, and pharmacokinetics who had participated parent trials. Patients enrolled under original...
Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited.To evaluate the efficacy safety of interleukin-13-targeted treatment tralokinumab monotherapy in AD.The 52-week, randomized, double-blinded, placebo-controlled, phase 3 ECZTRA 6 trial was conducted from July 17, 2018, through March 16, 2021, at 72 centers across 10 countries North America, Europe, Asia, Australia. Enrolled patients were 12 17 years old AD (Investigator's Global...
Abstract Background Atopic dermatitis (AD) is an inflammatory skin disease with significant unmet need. Blockade of the OX40–OX40 ligand (OX40L) costimulation pathway by targeting OX40L on antigen-presenting cells (APCs) a fully human noncytotoxic, nondepleting anti-OX40L monoclonal antibody (amlitelimab; SAR445229; KY1005) novel way to modulate persistent inflammation. Objectives To assess safety and efficacy amlitelimab over 16 weeks in adults AD phase IIa double-blind placebo-controlled...